David Oh, MD, PhD

Assoc. Professor in Residence

I am a physician-scientist focused on developing novel immunotherapies with enhanced activity and reduced toxicity, for patients with solid cancers.

Clinically, I see patients in the Cancer Immunotherapy Program where I lead numerous early phase trials, with a particular focus on adoptive cell therapies for solid tumors (CAR-T and TCR). I have also led trials of intratumoral immunotherapy and next-generation cytokine therapy.

In the laboratory, I run an extramurally funded translational program focused on the role of cytotoxic immune effectors in anti-tumor responses as well as immune-related adverse events (IRAEs) after immunotherapy. This work spans high-resolution multiomic interrogation and functional validation using patient samples, as well as murine model systems.

Education
Fellowship, 2017 - Hematology/Oncology, University of California, San Francisco
Residency, 2014 - Internal Medicine, University of California, San Francisco
MD/PhD, 2011 - Medicine, Physiology, Stanford University School of Medicine
AB, 2000 - Biochemical Sciences, Harvard College
Honors and Awards
  • Clinical Investigator Award, Damon Runyon Cancer Research Foundation, 2021
  • Young Investigator Award, Bladder Cancer Advocacy Network, 2018
  • Young Investigator Award, Prostate Cancer Foundation, 2018
  • Young Investigator Award, Conquer Cancer Foundation of American Society of Clinical Oncology, 2017
  • Merit Award, Conquer Cancer Foundation of American Society of Clinical Oncology, 2016
  • Molecular Pathology of Cancer T32, University of California, San Francisco, 2016
  • Clinical Fellow Award, University of California, San Francisco, 2015
Publications

  1. Montauti E, Oh DY, Fong L. CD4+ T cells in antitumor immunity. Trends in cancer 2024. PMID: 39242276


  2. Tsimberidou AM, Alayli FA, Okrah K, Drakaki A, Khalil DN, Kummar S, Khan SA, Hodi FS, Oh DY, Cabanski CR, Gautam S, Meier SL, Amouzgar M, Pfeiffer SM, Kageyama R, Yang E, Spasic M, Tetzlaff MT, Foo WC, Hollmann TJ, Li Y, Adamow M, Wong P, Moore JS, Velichko S, Chen RO, Kumar D, Bucktrout S, Ibrahim R, Dugan U, Salvador L, Hubbard-Lucey VM, O'Donnell-Tormey J, Santulli-Marotto S, Butterfield LH, Da Silva DM, Fairchild J, LaVallee TM, Padrón LJ, Sharma P. Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer. The Journal of experimental medicine 2024. PMID: 39190534


  3. He JY, Kim YJ, Mennillo E, Rusu I, Bain J, Rao AA, Andersen C, Law K, Yang H, Tsui J, Shen A, Davidson B, Kushnoor D, Shi Y, Fan F, Cheung A, Zhang L, Fong L, Combes AJ, Pisco AO, Kattah MG, Oh DY. Dysregulation of CD4+ and CD8+ resident memory T, myeloid, and stromal cells in steroid-experienced, checkpoint inhibitor colitis. Journal for immunotherapy of cancer 2024. PMID: 38642938


  4. Zenghua Fan, David Y. Oh, Anthony Wong, Katsuto Shinohara, Hao Nguyen, Caleb Hwang, Hewitt Chang, Alec Starzinski, Tony Li, Christopher De Leon, Marissa Gin, Eliezer Van Allen, Li Zhang, Rahaul R. Aggarwal, Terence W. Friedlander, Eric J. Small, Felix Y. Feng, Lawrence Fong. Abstract 4988: Responders to combination radiation and PD-1 blockade demonstrate reduced myeloid immunosuppression and enhanced interferon signaling in oligometastatic prostate cancer patients. Cancer research 2024. PMID:


  5. Mennillo E, Kim YJ, Lee G, Rusu I, Patel RK, Dorman LC, Flynn E, Li S, Bain JL, Andersen C, Rao A, Tamaki S, Tsui J, Shen A, Lotstein ML, Rahim M, Naser M, Bernard-Vazquez F, Eckalbar W, Cho SJ, Beck K, El-Nachef N, Lewin S, Selvig DR, Terdiman JP, Mahadevan U, Oh DY, Fragiadakis GK, Pisco A, Combes AJ, Kattah MG. Single-cell and spatial multi-omics highlight effects of anti-integrin therapy across cellular compartments in ulcerative colitis. Nature communications 2024. PMID: 38374043


  6. Vadim S Koshkin, Tanya Jindal, Jun Yan He, Li Zhang, Celine N. Galang, Divya Natesan, Vipul Kumar, Xiaolin Zhu, Jonathan Chou, Rahul Raj Aggarwal, Eric J. Small, Maxwell Meng, Sima P. Porten, David Yoonsuk Oh, Lawrence Fong, Terence W. Friedlander. Efficacy outcomes and biomarker analysis from phase II trial of escalating doses of neoadjuvant atezolizumab in patients with muscle-invasive urothelial carcinoma ineligible for cisplatin-based chemotherapy. Journal of Clinical Oncology 2024. PMID:


  7. Mennillo E, Kim YJ, Rusu I, Lee G, Dorman LC, Bernard-Vazquez F, Bain JL, Patel R, Andersen C, Rao A, Tamaki S, Tsui J, Shen A, Naser M, Eckalbar W, Cho SJ, Beck K, El-Nachef N, Lewin S, Selvig DR, Terdiman JP, Mahadevan U, Oh DY, Fragiadakis GK, Pisco A, Combes AJ, Kattah MG. Single-cell and spatial multi-omics identify innate and stromal modules targeted by anti-integrin therapy in ulcerative colitis. bioRxiv : the preprint server for biology 2023. PMID: 36711576


  8. Emperumal CP, Villa A, Hwang C, Oh D, Fong L, Aggarwal R, Keenan BP. Oral Toxicities of PSMA-Targeted Immunotherapies for The Management of Prostate Cancer. Clinical genitourinary cancer 2023. PMID: 38185609


  9. Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, Desai A, Kwon D, Kaushal S, Trihy L, Rastogi M, Ippisch R, Aslam M, Friedlander T, Feng F, Oh D, Cheung A, Small E, Evans M, Fong L, Hope TA. Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. The Lancet. Oncology 2023. PMID: 37922930


  10. Hassan R, Butler M, O'Cearbhaill RE, Oh DY, Johnson M, Zikaras K, Smalley M, Ross M, Tanyi JL, Ghafoor A, Shah NN, Saboury B, Cao L, Quintás-Cardama A, Hong D. Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results. Nature medicine 2023. PMID: 37501016


  11. Raffit Hassan, Marcus O. Butler, David Yoonsuk Oh, Roisin Eilish O'Cearbhaill, Lauren MacMullen, Erin Jeter, Udayan Guha, Viera P. Muzithras, Kevin Zikaras, Melissa Lynne Johnson, Janos Laszlo Tanyi, Azam Ghafoor, Robert Tighe, Munisha Smalley, Alfonso Quintas-Cardama, David S. Hong. Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors. Journal of Clinical Oncology 2023. PMID:


  12. Foy SP, Jacoby K, Bota DA, Hunter T, Pan Z, Stawiski E, Ma Y, Lu W, Peng S, Wang CL, Yuen B, Dalmas O, Heeringa K, Sennino B, Conroy A, Bethune MT, Mende I, White W, Kukreja M, Gunturu S, Humphrey E, Hussaini A, An D, Litterman AJ, Quach BB, Ng AHC, Lu Y, Smith C, Campbell KM, Anaya D, Skrdlant L, Huang EY, Mendoza V, Mathur J, Dengler L, Purandare B, Moot R, Yi MC, Funke R, Sibley A, Stallings-Schmitt T, Oh DY, Chmielowski B, Abedi M, Yuan Y, Sosman JA, Lee SM, Schoenfeld AJ, Baltimore D, Heath JR, Franzusoff A, Ribas A, Rao AV, Mandl SJ. Non-viral precision T?cell receptor replacement for personalized cell therapy. Nature 2022. PMID: 36356599


  13. Kwon H, Schafer JM, Song NJ, Kaneko S, Li A, Xiao T, Ma A, Allen C, Das K, Zhou L, Riesenberg B, Chang Y, Weltge P, Velegraki M, Oh DY, Fong L, Ma Q, Sundi D, Chung D, Li X, Li Z. Androgen conspires with the CD8+ T cell exhaustion program and contributes to sex bias in cancer. 2022. PMID: 35420889


  14. Susan F. Slovin, Tanya B. Dorff, Gerald Steven Falchook, Xiao X. Wei, Xin Gao, Rana R. McKay, David Yoonsuk Oh, Andreas Georg Wibmer, Matthew A. Spear, Joanne McCaigue, Devon J. Shedlock, Manjima Dhar, Julia Coronella, Christopher E. Martin, Majid Ghodussi, Ann Murphy, Eric M. Ostertag. Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology 2022. PMID:


  15. Wei J, Oh DY, Evans MJ. Preparation of Radiolabeled Antibodies for Nuclear Medicine Applications in Immuno-Oncology. 2022. PMID: 34837214


  16. Oh DY, Fong L. Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox. 2021. PMID: 34910940


  17. Oh DY, Fong L, Newell EW, Turk MJ, Chi H, Chang HY, Satpathy AT, Fairfax B, Silva-Santos B, Lantz O. Toward a better understanding of T cells in cancer. 2021. PMID: 34906313


  18. Zhao N, Bardine C, Lourenço AL, Wang YH, Huang Y, Cleary SJ, Wilson DM, Oh DY, Fong L, Looney MR, Evans MJ, Craik CS. In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PET. 2021. PMID: 34729407


  19. Keenan BP, VAN Loon K, Khilnani AD, Fidelman N, Behr SC, Atreya CE, Oh DY. Molecular and Radiological Features of Microsatellite Stable Colorectal Cancer Cases With Dramatic Responses to Immunotherapy. Anticancer research 2021. PMID: 34083289


  20. Apostolia Maria Tsimberidou, Alexandra Drakaki, Danny Khalil, Shivaani Kummar, F. Stephen Hodi, David Yoonsuk Oh, Christopher R. Cabanski, Michael Tezlaff, Theresa LaVallee, Marko Spasic, Leo Nissola, Lacey J. Kitch, Nicholas L. Bayless, Cheryl Selinsky, Jennifer C Ayran, Jill O'Donnell-Tormey, Vanessa M. Hubbard-Lucey, Ute Dugan, James Patrick Allison, Padmanee Sharma. An exploratory study of nivolumab (nivo) with or without ipilimumab (ipi) according to the percentage of tumoral CD8 cells in advanced metastatic cancer. Journal of Clinical Oncology 2021. PMID:


  21. Divya V Natesan, Li Zhang, David Yoonsuk Oh, Sima P. Porten, Maxwell Meng, Raj Pruthi, Matthew R. Cooperberg, Peter Carroll, Jonathan Chou, Hala Borno, Rohit Bose, Arpita Desai, Daniel H Kwon, Anthony C. Wong, Felix Y Feng, Rahul Raj Aggarwal, Eric Jay Small, Lawrence Fong, Terence W. Friedlander, Vadim S Koshkin. Updated results of phase II trial using escalating doses of neoadjuvant atezolizumab for cisplatin-ineligible patients with nonmetastatic urothelial cancer (NCT02451423). Journal of Clinical Oncology 2021. PMID:


  22. de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, Koshkin VS. TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor. Journal for immunotherapy of cancer 2021. PMID: 33980590


  23. Baik AH, Tsai KK, Oh DY, Aras MA. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors. Volume 135 of Issue 5. Clinical science (London, England : 1979) 2021. PMID: 33686402


  24. Oh DY. CD38 as a Novel Immunosuppressive Target in Prostate Cancer. European urology 2021. PMID: 33637364


  25. Vadim S Koshkin, Divya Natesan, Li Zhang, David Yoonsuk Oh, Sima P. Porten, Maxwell Meng, Raj Pruthi, Rahul Raj Aggarwal, Eric Jay Small, Lawrence Fong, Terence W. Friedlander. Phase II trial of escalating doses of neoadjuvant atezolizumab for patients with non-metastatic urothelial carcinoma ineligible for cisplatin-based neoadjuvant chemotherapy. Journal of Clinical Oncology 2021. PMID:


  26. Ivan de Kouchkovsky, Li Zhang, Errol Philip, Francis Wright, Daniel Myung Kim, Divya Natesan, Daniel Kwon, Hansen Ho, Son Ho, Emily Chan, Sima P. Porten, Arpita Desai, Franklin W. Huang, Jonathan Chou, David Yoonsuk Oh, Raj Pruthi, Lawrence Fong, Eric Jay Small, Terence W. Friedlander, Vadim S Koshkin. TERT promoter mutation as a prognostic marker in patients with advanced urothelial carcinoma treated with immune checkpoint inhibitors. Journal of Clinical Oncology 2021. PMID:


  27. Naidus E, Bouquet J, Oh DY, Looney TJ, Yang H, Fong L, Standifer NE, Zhang L. Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients. Cancer immunology, immunotherapy : CII 2021. PMID: 33420629


  28. Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sjöström M, Quigley DA, Chou J, Beer TM, Rettig MB, Gleave ME, Evans CP, Lara PN, Chi KN, Reiter RE, Alumkal JJ, Ashworth A, Aggarwal R, Small EJ, Daugherty PS, Ribas A, Oh DY, Shon JC, Feng FY. Autoantibody landscape in patients with advanced prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2020. PMID: 32967941


  29. Zhang L, Kandadi H, Yang H, Cham J, He T, Oh DY, Sheikh NA, Fong L. Long-term Sculpting of the B-cell Repertoire Following Cancer Immunotherapy in Patients Treated with Sipuleucel-T. Cancer immunology research 2020. PMID: 32967912


  30. Wei J, Wang YH, Lee CY, Truillet C, Oh DY, Xu Y, Ruggero D, Flavell RR, VanBrocklin HF, Seo Y, Craik CS, Fong L, Wang CI, Evans MJ. An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers. Molecular imaging and biology 2020. PMID: 32813112


  31. Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L. Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. Cell 2020. PMID: 32497499


  32. Cham J, Zhang L, Kwek S, Paciorek A, He T, Fong G, Oh DY, Fong L. Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies. Journal for immunotherapy of cancer 2020. PMID: 32376721


  33. Errol James Philip, Francis Wright, Daniel Myung Kim, Daniel Kwon, Hansen Ho, Son Ho, Edna Cheung, Emily Chan, Sima P. Porten, Anthony C. Wong, Hala Borno, Arpita Desai, Jonathan Chou, David Yoonsuk Oh, Rahul Raj Aggarwal, Lawrence Fong, Eric Jay Small, Terence W. Friedlander, Vadim S Koshkin. Efficacy of immune checkpoint inhibitors (ICIs) in rare histological variants of bladder cancer. Journal of Clinical Oncology 2020. PMID:


  34. Daniel Kwon, Francis Wright, Li Zhang, Jonathan Chou, Hala Borno, Arpita Desai, David Yoonsuk Oh, YaoYao Guan Pollock, Rohit Bose, Franklin W. Huang, Thomas Hope, Terence W. Friedlander, Lawrence Fong, Felix Y Feng, Eric Jay Small, Rahul Raj Aggarwal, Vadim S Koshkin. Treatment outcomes in metastatic prostate cancer patients with DNA damage repair mutations. Journal of Clinical Oncology 2020. PMID:


  35. Looney TJ, Topacio-Hall D, Lowman G, Conroy J, Morrison C, Oh D, Fong L, Zhang L. TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer. Frontiers in immunology 2020. PMID: 31993050


  36. Hammami MB, Gill R, Thiruvengadam N, Oh DY, Beck K, Mahadevan U, Kattah MG. Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin. Digestive diseases and sciences 2019. PMID: 30778872


  37. Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, Tamaki W, Liu E, Roybal KT, Seagal J, Chen M, Hagihara K, Wei XX, DuPage M, Kwek SS, Oh DY, Daud A, Tsai KK, Wu C, Zhang L, Fasso M, Sachidanandam R, Jayaprakash A, Lin I, Casbon AJ, Kinsbury GA, Fong L. Clonal Deletion of Tumor-Specific T Cells by Interferon-? Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. Immunity 2019. PMID: 30737146


  38. Oh DY, Fong L. Immunity in the Time of Metastases. Immunity 2018. PMID: 30566878


  39. Hagihara K, Chan S, Zhang L, Oh DY, Wei XX, Simko J, Fong L. Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer. Oncoimmunology 2018. PMID: 30546940


  40. David Yoonsuk Oh, Serena S. Kwek, Serghei Mangul, Siddharth S. Raju, Sasha Targ, Arun Burra, Eric Chow, Dvir Aran, Sima Porten, Maxwell V. Meng, Terence W. Friedlander, Chun Jimmie Ye, Lawrence Fong. Abstract 4688: Single-cell discrimination of altered human T cell states in the bladder tumor microenvironment. Immunology 2018. PMID:


  41. David Y. Oh, Li Zhang, Jason Cham, Alan Paciorek, Mark Klinger, Malek Faham, Susan F. Slovin, Lawrence Fong. Abstract 1694: Systemic granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment increases T cell receptor diversity in localized and metastatic prostate cancer patients. Immunology 2017. PMID:


  42. Li Zhang, Sounak Chakraborty, Jason Cham, David Oh, Nadeem Sheikh, Lawrence Fong. Abstract 549: Clustering analysis of next-generation sequencing T cell repertoire data in sipuleucel-T treated prostate cancer patients. Bioinformatics and Systems Biology 2017. PMID:


  43. Oh DY,* Cham J,* Zhang L, Fong G, Kwek SS, Klinger M, Faham M, Fong L. *co-first author.. Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire Cancer Res. 2017. PMID:


  44. David Y. Oh, Jason Cham, Li Zhang, Grant Fong, Mark Klinger, Malek Faham, Lawrence Fong. Abstract 4362: T cell repertoire diversification is associated with immune related toxicities following immune checkpoint inhibition in metastatic cancer patients. Immunology 2016. PMID:


  45. David Yoonsuk Oh, Jason Cham, Li Zhang, Grant Fong, Mark Klinger, Malek Faham, Lawrence Fong. Association between T cell repertoire diversification and both clinical response as well as toxicity following immune checkpoint blockade in metastatic cancer patients. Journal of Clinical Oncology 2016. PMID:


  46. Oh DY, Venook AP, Fong L. On the Verge: Immunotherapy for Colorectal Carcinoma. Journal of the National Comprehensive Cancer Network : JNCCN 2015. PMID: 26285242


  47. Ehrlich LI,* Oh DY,* Weissman IL, Lewis RS. *co-first author.. Differential contribution of chemotaxis and substrate restriction to segregation of immature and mature thymocytes Immunity. 2009. PMID:


  48. Bhakta NR, Oh DY, Lewis RS. Calcium oscillations regulate thymocyte motility during positive selection in the three-dimensional thymic environment. Nature immunology 2005. PMID: 15654342


  49. Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Volume 112 of Issue 5. Cell 2003. PMID: 12628186


  50. Beresford PJ, Zhang D, Oh DY, Fan Z, Greer EL, Russo ML, Jaju M, Lieberman J. Granzyme A activates an endoplasmic reticulum-associated caspase-independent nuclease to induce single-stranded DNA nicks. Volume 276 of Issue 46. The Journal of biological chemistry 2001. PMID: 11555662


  51. Gommerman JL,* Oh DY,* Zhou X, Tedder TF, Maurer M, Galli SJ, Carroll MC. *co-first author.. A role for CD21/CD35 and CD19 in responses to acute septic peritonitis: a potential mechanism for mast cell activation J Immunol. 2000. PMID: